drugset / Trial / NCT05249114
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
Phase 1
Active not recruiting
6 enrolled
Providence Health & Services
Advanced Accelerator Applications · collabExelixis · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The phase I objective of this study is to establish the maximal tolerated dose (MTD) of cabozantinib in 20 mg, 40 mg and 60 mg dose escalation cohorts in combination with Lu-177 dotatate at a standard dose of 7.4 GBq in four (4) 8-week cycles followed by continuation cabozantinib.
Timeline
- Start
- 2022-12-28
- Primary completion
- 2027-12
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 177Lu-DOTATATE | Peptide | 7400 mbq | Intravenous |
| Subject | Cabozantinib | Small molecule | 20 mg | — |
| Subject | Cabozantinib | Small molecule | 40 mg | — |
| Subject | Cabozantinib | Small molecule | 60 mg | — |